

PARTNER PLATFORM High Throughput Screening / Hit to lead

Center for Drug Discovery and Development (C3D)

General information

Administrative information	
Structure	Cancer Research Center of Lyon (CRCL)
Address	28 rue Laennec 69008 Lyon
Website	https://www.crcl.fr/les-plateformes/c3d-
	centre-de-decouverte-et-de-
	developpement-du-medicament/
Manager	Stéphane Giraud
Contact	stephane.giraud@lyon.unicancer.fr
Date of implementation	October 2012

Labels / quality approach		
IBiSA	Yes, November 2023	
ISO 9001 certification	Yes / No + date of obtention	
National networks	Yes / No + date of obtention	
International networks	Specify	
Other	GDR ChemBio	

Team		
Number of researchers	1 (permanent)	
Number of engineers	2 (permanent)	
Number of technicians		
Number of administrative staff	1 (shared with other CRCL	
	platforms)	
Other	Specify	

Main achievements	s
Number of screenings performed since creation	10
Number of screenings performed per year	1-2
Fields of expertise / therapeutic areas	

Based on the targets identified by project leaders, the C3D platform supports academic researchers and private companies in the development of new therapies in the field of oncology, in the form of small chemical molecules or therapeutic antibodies. One of the platform's key features is its ability to support project leaders from target identification up to the clinic. The platform has all the necessary expertise to intervene at various stages in the development of these new therapies, ranging from compound or hybridoma screening to hit-lead optimization, mechanism of action identification, pharmacological efficacy, and regulatory non-clinical development.17 projects have been successfully performed since the creation of the platform.



Scientific Information

Chemical Library		
Description of the collection (number of chemical molecules, natural, royalty-free products,		
known synthesis methods, etc)		
Prestwick library, 1,200 FDA approved compounds • Natural like compounds: 1,200 development drugs): 590 compounds • Fr-PF compounds.	Kinase inhibitor (approved or under	
Conditioning	96 or 384 well-plates	
Database (structure, accessibility	Structure databases for all our libraries.	
conditions)	Structure available to our collaborators.	
Member of the National Chemical Library	No	

	of a		
To I	E a	L WILL	-

Targets for the screening service (e.g. protein targets, cell targets, etc.)

Target-based and Cell-based assay – Hight content screening – Phenotypic screening Activities (e.g. cloning, protein expression, obtaining cell lines, management and storage of lines, cell culture, etc.)

Activities of the platform linked to the screening (the scope of actions is broader): cloning, protein production and purification. Design and implementation of primary screening assays on isolated target or cell lines. Cell culture and storage of cell lines. High content screening analysis. Screening results analyzed using TIBCO spotfire.

High throughput screening

Number of measurements/days (approx.) 2000-4000

Biological tests proposed (e.g. in vitro enzymatic tests, cell tests (binding tests, cell survival, image analysis, etc)

In vitro:

Enzymatic assays, protein-protein interaction inhibition. Binding affinity determination. In cellulo:

Phenotypic screening adapted to the cellular pathway targeted; apoptosis; cell viability assays; in cellulo protein protein interactions (BiFc).

Technologies / Equipment (robots, automats, etc.)

TRIC, BLI, BiFc, luminescent, fluorescent (HTRF for example), colorimetric methods, High Content screening (HCS).

Equipment:

Automated liquid handling (robotic platform TECAN EVO150) • Multi-technology microplate readers (96 – 384 wells, TECAN SPARK, TECAN Infinite 500) • Dianthus (Nanotemper) • Octet 96 (Sartorius) • HP D300 dispenser for titration (TECAN) • Cell culture room • HCS platform: Opera Phenix Perkin Elmer

Access	
Site teams	Yes
External academic teams	Yes
Private Outdoor Teams	Yes

Training courses offered
HTRF and TRIC technologies; Assay robotization